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Background: Ultrasound guided fine-needle aspiration (USFNA) biopsy of thyroid nodules often gives a result of
indeterminate pathology, placing thyroid specialists in difficult management situations. The aim of this study is to
evaluate the incidence of malignancy in patients undergoing surgery and to correlate these results with the McGill
Thyroid Nodule Score (MTNS).
Methods: We performed a retrospective study comparing USFNA results, MTNS and histopathology of patients
undergoing thyroid surgery between 2010 and 2012. Pre-operative USFNA results were divided into three
subgroups: benign, indeterminate and suspicious for/malignant. The indeterminate USFNA subgroup comprised of
Bethesda type III (atypia of undetermined significance) and Bethesda type IV (follicular neoplasms, including Hurthle
cell neoplasms) lesions. Post-operative histopathology was divided into benign or malignant groups.
Results: Of the 437 patient charts reviewed, 57.0% had an indeterminate USFNA biopsy. Within the indeterminate
group, the malignancy rate was 39.8%. For indeterminate USFNA, the median MTNS was 7 (32% risk of malignancy)
for benign nodules and 9 (63% risk of malignancy) for malignant nodules on post-operative histopathology (p < 0.05).
Conclusion: The rate of malignancy in operated patients with an indeterminate USFNA result was 39.8%. The MTNS
can be of value to thyroid specialists in pre-operative decision-making when dealing with an indeterminate result of a
thyroid nodule on USFNA.
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Ultrasound guided fine-needle aspiration (USFNA) bi-
opsy is the first-line modality in the work-up of thyroid
nodules [1,2]. Biopsy results are often categorised into
three main groups: benign, malignant or indeterminate,
with an indeterminate USFNA result posing diagnostic
and management dilemmas. Given that 15% to 48% of
thyroid nodule biopsies are indeterminate [2-7], this is
not an infrequent situation for thyroid specialists to en-
counter. In order to estimate the risk of malignancy of a
thyroid nodule, the McGill Thyroid Nodule Score (MTNS)
was developed. This scoring system combines patient his-
tory, demographics, imaging and USFNA results [8]. Each* Correspondence: rickul.varshney@gmail.com
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unless otherwise stated.of the 22 variables in the MTNS are assigned a weighted,
relative point score based on the robustness of the current
supporting evidence for that risk factor (Figure 1). The
MTNS has been shown to correlate with the risk of malig-
nancy in a large series of patients [8].
In this study, our objective was to evaluate the rate of
indeterminate nodules and incidence of malignancy
among these patients undergoing thyroid surgery at our
center. Next, we aimed to assess whether the MTNS can
help predict the likelihood of malignancy in such pa-
tients with indeterminate cytology.Methods
We performed a retrospective review of 559 consecutive
patients who underwent thyroid surgery at the McGill
University teaching hospitals between 2010 and 2012.
The study received approval by the hospitals’ Researchal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 The McGill Thyroid Nodule Score (MTNS). PET: positron emission tomography; TSH: Thyroid Stimulating Hormone.
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cluded as a MTNS was not calculated pre-operatively or
had an unsatisfactory USFNA result (Bethesda type I).
As a result, a total of 437 patients were analyzed. Of
note, patients with an indeterminate USFNA biopsy who
did not undergo surgery were excluded from the study.
The patients analyzed were divided into three groups
based on pre-operative USFNA diagnosis: benign (Bethesdatype II), indeterminate (Bethesda types III-IV), and suspi-
cious for malignancy/malignant (Bethesda types V-VI).
The Bethesda type IV lesions included both follicular neo-
plasms/suspicious for follicular neoplasms and Hurthle
cell neoplasms. Post-operative diagnoses were divided into
benign and malignant based on histopathology. All cases
of malignancy were included: follicular, papillary, medullary
and anaplastic carcinoma. Demographic profiles, MTNS
Table 2 Distribution of FNAB diagnosis and post-operative
pathology diagnoses







Benign (Bethesda II) 25 (75.8%) 8 (24.2%)
Indeterminate
(Bethesda III, IV)
150 (60.2%) 99 (39.8%)
Malignant/Suspicious for
malignancy (Bethesda V, VI)
6 (3.8%) 149 (96.1%)
Whole population
(Bethesda, II, III, IV, V, VI)
181 (41.4%) 256 (58.6%)
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were noted for each patient. An experienced thyroid can-
cer pathologist reviewed all histological specimens.
For data analysis, six subgroups of patients were cre-
ated: (1) benign and indeterminate USFNA (Bethesda
type II, III, IV) with benign final diagnoses; (2) benign
and indeterminate USFNA (Bethesda type II, III, IV)
with malignant final diagnoses; (3) benign USFNA (Bethesda
type II) with benign final diagnoses; (4) benign USFNA
(Bethesda type II) with malignant final diagnoses; (5) inde-
terminate USFNA (Bethesda type III and IV) with benign
final diagnoses; (6) indeterminate USFNA (Bethesda type
III and IV) with malignant final diagnoses. Median and
mean MTNS scores were calculated for each group. We
compared group 1 with 2, group 3 with 4 and group 5
with 6 in order to determine if the MTNS allows for a bet-
ter prediction of malignancy when faced with an indeter-
minate USFNA result. SPSS 20.0 was used for statistical
analysis using the independent t-test. A p < 0.05 was con-
sidered to indicate statistical significance.Results
There were 437 patients analyzed in this study, 181
(39 male, 142 female) with a benign final diagnosis and
256 (54 male, 202 female) with a malignant final diagno-
sis. The average patient age was 53.3 (±16.1) years old in
the benign group and 55.1 (±16.4) years old in the ma-
lignant group. There was no statistical difference in age
or gender between groups (Table 1).
The pre-operative USFNA classification was as follows:
33 (7.6%) benign (Bethesda type II), 249 (57.0%) indeter-
minate (Bethesda type III and IV) and 155 (35.5%) ma-
lignant/suspicious for malignancy (Bethesda type V and
VI). Post-operatively, the malignancy rate was 58.6% (see
Table 2).
The median and mean MTNS for each subgroup of
patients is presented in Table 3. The corresponding esti-
mated risk of cancer using the MTNS is also provided; a
percentage is conferred to each score. The average MTNS
was 7 for the benign final diagnosis group and 9 for the
malignant final diagnosis group (p <0.001). These MTNS
values conferred a pre-operative estimated risk of having a
malignant nodule of 32% in the benign group and 63% in
the malignant group. Similarly, the median MTNS for pa-
tients with an indeterminate USFNA result with benignTable 1 Patient demographics distributed into post-
operative benign or malignant diagnoses for all patients
Benign Malignant p-value
Gender Male 39 (21.5%) 54 (21.1%) p > 0.05
Female 142 (78.5%) 202 (78.9%)
Age 53.2 (±16.1) 55.1 (±16.4) p > 0.05final pathology was also 7 whereas it was 9 for patients
with malignant disease post-operatively (p = 0.001).Discussion
USFNA is an integral part in the work-up of thyroid
nodules [1,2]. When an USFNA biopsy indicates an in-
determinate result, there is often uncertainty in the risk
of malignancy. According to some authors, up to 74% of
patients with indeterminate nodules undergo surgery [3]
largely due to the limitations of USFNA. However, not
all indeterminate nodules are malignant. Tutuncu et al.
reported an incidence of 33.3% and 23.0% for malig-
nancy in Hurthle cell lesions and follicular lesions, re-
spectively [9]. Similarly, Sugino et al. demonstrated a
28% incidence of malignancy in their indeterminate
pathology group [10]. Notably, these studies included
only patients undergoing thyroid surgery. However, the
risk of malignancy needs to be weighed against the 2 to
10% risk of serious surgical complications [5] such as re-
current laryngeal nerve injury, hypocalcemia, as well as
the lifelong need for thyroid hormone replacement.
Our study shows that 57.0% of patients with pre-
operative USFNA results are indeterminate (Bethesda III
and IV), obscuring clinical management. This rate of in-
determinate nodules is higher than that reported in the
literature, but rates as high as 48% have been reported
[7]. This is likely due to a selected population of patients
undergoing surgery. At our institution, the routine use
of HBME staining is not performed and may further ex-
plain the high rate of indeterminate nodules. Moreover,
the categories of atypia of undetermined significance
(AUS, Bethesda III) and follicular lesion of undetermined
significance/Hurthle cell lesion of undetermined signifi-
cance (FLUS/HUS, Bethesda IV) are often reported with
a wide range of rates in the literature [11-13] due to the
heterogeneity of their characteristics and subjectivity in
the diagnostic criteria. Thus, it was deemed appropriate
to analyze these biopsy results together when assessing
malignancy risk and the MTNS until more robust
Table 3 Median and mean MTNS scores for each subgroup of patients
FNAB Post-operative diagnosis Median MTNS (Mean) Estimated risk of cancer p-value
Whole population (Bethesda II, III, IV) Benign 7.0 (7.76) 32% p <0.001
Malignant 9 (9.38) 63%
Benign (Bethesda II) Benign 6 (6.68) 32% p = 0.428
Malignant 5 (4.50) 32%
Indeterminate (Bethesda III, IV) Benign 7 (7.94) 32% p = 0.001
Malignant 9 (9.78) 63%
p <0.05 considered significant.
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are established.
For patients with an indeterminate USFNA result
(Bethesda type III and IV), the median MTNS for all pa-
tients with benign disease post-operatively was 7 (32% risk
of malignancy) and 9 for patients with malignant disease
(63% risk of malignancy). Although many would argue
that even a 32% risk of malignancy is considered signifi-
cant and requires action, the difference lies in the mode of
intervention to be chosen. In cases of a MTNS of 7, a
diagnostic hemi-thyroidectomy would most likely be the
therapeutic option chosen. With a MTNS of 9, a higher
risk of thyroid cancer likely exists. In such cases, a dis-
cussion with patients about the utility of a total thyroid-
ectomy may be advocated, precluding the need for
completion thyroidectomies in cases of malignancy. Des-
pite this, it remains unclear of the significance of an inde-
terminate USFNA with a MTNS score of 8.
With regards to malignancy rates in our population,
the malignancy rate for benign (Bethesda II), indeter-
minate (Bethesda III-IV) and suspicious for malignancy/
malignant (Bethesda V-VI) were 24.2%, 39.8% and 96.1%,
respectively. This is in line with results by Al-Shraim
et al. who reported rates of 10.3%, 25.0% and 86.4%,
respectively [11]. Our 39.8% malignancy rate in the indeter-
minate group is also comparable to reports by Granados-
Garcia et al. who showed a 40% rate of malignancy [14],
Rossi et al. who reported a 35.7% risk of malignancy [15]
and Lee et al. who demonstrated a 46.3% incidence of can-
cer for indeterminate nodules [2]. The high rate of inde-
terminate nodules along with a significant incidence of
malignancy within this population reinforces the need for
ancillary tools to help guide management.
For these reasons, there has been a rise in diagnostic
tests available to thyroid specialists in the past few years.
One such tool is the 4-gene classifier (BRAF, RET/PTC,
PAX8/PPARϒ, and RAS) [16]. Genetic markers have a
high specificity and positive predictive value [5] and can
improve diagnostic accuracy. However, they have a low
sensitivity and negative predictive value [5,16]. A more
recent advancement is the Afirma gene expression clas-
sifier (Veracyte, Inc., San Francisco, USA) which mea-
sures mRNA transcript expression levels of 142 genes. Ithas shown to have a high sensitivity with moderate spe-
cificity [5]. Nonetheless, a major obstacle to their wide-
spread use is the high costs [6] associated with such
tests.
Another tool available to guide clinical management of
thyroid nodules is MTNS [8]. This non-validated scoring
system uses evidence-based risk factors for thyroid can-
cer to estimate the risk of malignancy. It is unique as it
does not solely rely on cytology results. The MTNS is
based on risk factors for thyroid cancer categorized into
8 clinical/laboratory parameters, 8 imaging features (ultra-
sound/positron emission tomography scan) and 6 histo-
pathological criteria (Figure 1). These risk factors are
based on the American Thyroid Association guidelines as
well as a literature review on thyroid malignancy risk fac-
tors. It was developed by a multidisciplinary committee at
the McGill University. Sands et al. demonstrated a PPV
and specificity for carcinoma of 66% and 13% for scores
>4, 81% and 66% for scores >8, 96% and 96% for scores
>14 and 100% and 100% for scores >19, respectively [8].
Certain factors limit the generalization of this study.
Firstly, this is a retrospective review of patients undergo-
ing thyroid surgery with an indeterminate USFNA. In-
herently, these patients may be at an increased risk of
malignancy. Secondly, not all patients seen at our insti-
tution have a calculated MTNS, resulting in patients be-
ing excluded from analysis. Also, our difference of 2
points on the MTNS, though statistically significant,
must be retain as an average difference when applied in
clinical practice. As such, a small difference in MTNS
can predict for a benign or malignant nodule, changing
therapeutic options for individual patients.
Modern diagnostic tests to help direct the need for
and extent of surgery, particularly in patients with inde-
terminate cytology are needed. Furthermore, validated
risk stratification algorithms, similar to the MTNS, are
useful in the interim until such tests are widely available.
Conclusion
Our study shows that when looking at indeterminate
thyroid nodules, the MTNS is able to demonstrate an in-
creased pre-operative risk of carcinoma for nodules
found to be malignant. Based on these results, we suggest
Varshney et al. Journal of Otolaryngology - Head and Neck Surgery  (2015) 44:2 Page 5 of 5that the MTNS be considered as a tool to guide the man-
agement of indeterminate thyroid nodules, as it not only
refines the pre-operative estimated risk of cancer, but also
clarifies communication between physicians and patients.
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